Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 48 recruiting now official registry

Anatomic Stage III Breast Cancer AJCC v8 clinical trials

48 of 85 indexed Anatomic Stage III Breast Cancer AJCC v8 trials are currently recruiting.

85 US clinical trials · 48 currently recruiting

Anatomic Stage III Breast Cancer AJCC v8 is the subject of 85 registered US clinical trials on ClinicalTrials.gov, 48 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 14 of these trials.

The research picture

Anatomic Stage III Breast Cancer AJCC v8 has 85 registered US clinical trials, 48 of them open to new participants right now, about 56% of the total.

48
recruiting participants now
56%
of trials open to enrollment
8
in Phase 3–4 (later-stage)
14
top sponsor: National Cancer Institute (NCI)
Phase 120Phase 223Phase 37Phase 41

Active & Recent Trials

85 total, page 2 of 2

ACTIVE NOT RECRUITING Phase 3 1,167 participants

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Alliance for Clinical Trials in Oncology

NCT04379570

ACTIVE NOT RECRUITING Phase 2 1,100 participants

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

M.D. Anderson Cancer Center

NCT01334021

ACTIVE NOT RECRUITING Phase 3 1,056 participants

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Alliance for Clinical Trials in Oncology

NCT04457596

ACTIVE NOT RECRUITING Phase 3 608 participants

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

National Cancer Institute (NCI)

NCT02115282

ACTIVE NOT RECRUITING NA 565 participants

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

SWOG Cancer Research Network

NCT05568472

ACTIVE NOT RECRUITING NA 543 participants

Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions

Alliance for Clinical Trials in Oncology

NCT04549571

ACTIVE NOT RECRUITING NA 400 participants

Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors

Ohio State University Comprehensive Cancer Center

NCT04906200

ACTIVE NOT RECRUITING NA 332 participants

A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer

Thomas Jefferson University

NCT04086875

ACTIVE NOT RECRUITING NA 256 participants

Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study

M.D. Anderson Cancer Center

NCT04754412

ACTIVE NOT RECRUITING Phase 2 249 participants

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

ECOG-ACRIN Cancer Research Group

NCT04001829

ACTIVE NOT RECRUITING Phase 2 235 participants

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

ECOG-ACRIN Cancer Research Group

NCT05710328

ACTIVE NOT RECRUITING Phase 3 146 participants

Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients

Mayo Clinic

NCT04443413

ACTIVE NOT RECRUITING NA 95 participants

Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy

M.D. Anderson Cancer Center

NCT05049746

ACTIVE NOT RECRUITING Phase 2 81 participants

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

National Cancer Institute (NCI)

NCT02849496

ACTIVE NOT RECRUITING NA 61 participants

Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer

Ohio State University Comprehensive Cancer Center

NCT03786354

ACTIVE NOT RECRUITING NA 60 participants

A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors

University of Washington

NCT06392789

ACTIVE NOT RECRUITING Phase 1 57 participants

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

NCT02453620

ACTIVE NOT RECRUITING NA 49 participants

Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial

Fred Hutchinson Cancer Center

NCT06643455

ACTIVE NOT RECRUITING Phase 2 33 participants

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

University of Washington

NCT05455658

ACTIVE NOT RECRUITING Phase 2 30 participants

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

NCT06630325

ACTIVE NOT RECRUITING NA 30 participants

Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer

M.D. Anderson Cancer Center

NCT05025059

ACTIVE NOT RECRUITING Phase 1 24 participants

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

NCT04345913

ACTIVE NOT RECRUITING Phase 1 23 participants

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT03218826

ACTIVE NOT RECRUITING Phase 1 18 participants

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

University of Washington

NCT04673448

ACTIVE NOT RECRUITING Phase 2 17 participants

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

NCT03179904

ACTIVE NOT RECRUITING Phase 2 8 participants

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Mayo Clinic

NCT03941730

COMPLETED NA 452 participants

Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer

M.D. Anderson Cancer Center

NCT00507923

COMPLETED Phase 2 130 participants

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

NCT04862585

COMPLETED NA 50 participants

An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors

Ohio State University Comprehensive Cancer Center

NCT05012176

COMPLETED NA 45 participants

An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information

Fred Hutchinson Cancer Center

NCT06193070

COMPLETED NA 23 participants

Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer

Wake Forest University Health Sciences

NCT03505671

COMPLETED Phase 1 20 participants

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

M.D. Anderson Cancer Center

NCT03620201

COMPLETED Phase 1 18 participants

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

M.D. Anderson Cancer Center

NCT03207529

COMPLETED Phase 1 15 participants

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

M.D. Anderson Cancer Center

NCT03774472

COMPLETED Phase 1 11 participants

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Ohio State University Comprehensive Cancer Center

NCT04205903

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 20
Phase 2 23
Phase 3 7
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Anatomic Stage III Breast Cancer AJCC v8 Trial Landscape

85 indexed Anatomic Stage III Breast Cancer AJCC v8 studies · 48 recruiting (56%).

Phase mix: 8 late (III/IV) vs 43 early (I/II).

Top sponsor: National Cancer Institute (NCI) (14 trials), 9 others listed. 35 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Anatomic Stage III Breast Cancer AJCC v8?

PlainTrial tracks 85 US clinical trials for Anatomic Stage III Breast Cancer AJCC v8, of which 48 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Anatomic Stage III Breast Cancer AJCC v8?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.